x
Norris Cotton Cancer CenterNorris Cotton Cancer Center
In This Section
 
Phase III Randomized Study of Four Weeks High Dose IFN-�2b in Stage T2b No, T3a-bNo, T4a-b No, and T1-4, N1a, 2a (microscopic) Melanoma
Principal Investigator (?)
Arrick, Bradley
Study Number
E1697
Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically. PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery. 
Phase (?)
Phase III
Sponsor (?)
Contact

Neal Wilson

Available at the following location(s)

Southwestern Vermont

View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.

0